156 related articles for article (PubMed ID: 28489587)
1. NGS based identification of mutational hotspots for targeted therapy in anaplastic thyroid carcinoma.
Tiedje V; Ting S; Herold T; Synoracki S; Latteyer S; Moeller LC; Zwanziger D; Stuschke M; Fuehrer D; Schmid KW
Oncotarget; 2017 Jun; 8(26):42613-42620. PubMed ID: 28489587
[TBL] [Abstract][Full Text] [Related]
2. Synergistic effects of the combination of trametinib and alpelisib in anaplastic thyroid cancer with BRAF and PI3KCA co-mutations.
Chen CP; Lin SF; Yeh CN; Huang WK; Pan YR; Hsiao YT; Lo CH; Wu CE
Heliyon; 2024 Apr; 10(7):e29055. PubMed ID: 38576565
[TBL] [Abstract][Full Text] [Related]
3. Next-generation sequencing in thyroid cancers: do targetable alterations lead to a therapeutic advantage?: A multicenter experience.
Moore A; Bar Y; Maurice-Dror C; Finkel I; Goldvaser H; Dudnik E; Goldstein DA; Gordon N; Billan S; Gutfeld O; Wolf I; Popovtzer A
Medicine (Baltimore); 2021 Jun; 100(25):e26388. PubMed ID: 34160418
[TBL] [Abstract][Full Text] [Related]
4. Primary Squamous Cell Carcinoma of the Thyroid Has a Molecular Genetic Profile Distinct From That of Anaplastic Thyroid Carcinoma: A Whole Exome Sequencing and Gene Expression Profiling Study.
Ye M; Guo Z; Xu J; Jin Y; He X; Ge M
Am J Surg Pathol; 2024 May; ():. PubMed ID: 38775423
[TBL] [Abstract][Full Text] [Related]
5. Pan-Genomic Sequencing Reveals Actionable
Stenman A; Yang M; Paulsson JO; Zedenius J; Paulsson K; Juhlin CC
Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944959
[TBL] [Abstract][Full Text] [Related]
6. Genomically driven precision medicine to improve outcomes in anaplastic thyroid cancer.
Pinto N; Black M; Patel K; Yoo J; Mymryk JS; Barrett JW; Nichols AC
J Oncol; 2014; 2014():936285. PubMed ID: 25276134
[TBL] [Abstract][Full Text] [Related]
7. Molecular-targeted therapy for advanced anaplastic thyroid cancer combined with nutritional support.
Maegawa Y; Higashiguchi T; Futamura A; Tsuzuki N; Murai M
Fujita Med J; 2019; 5(1):25-29. PubMed ID: 35111497
[TBL] [Abstract][Full Text] [Related]
8. Update on anaplastic thyroid carcinoma: morphological, molecular, and genetic features of the most aggressive thyroid cancer.
Ragazzi M; Ciarrocchi A; Sancisi V; Gandolfi G; Bisagni A; Piana S
Int J Endocrinol; 2014; 2014():790834. PubMed ID: 25214840
[TBL] [Abstract][Full Text] [Related]
9. Targeted next generation sequencing identifies somatic mutations and gene fusions in papillary thyroid carcinoma.
Lu Z; Zhang Y; Feng D; Sheng J; Yang W; Liu B
Oncotarget; 2017 Jul; 8(28):45784-45792. PubMed ID: 28507274
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic modifications in poorly differentiated and anaplastic thyroid cancer.
Sasanakietkul T; Murtha TD; Javid M; Korah R; Carling T
Mol Cell Endocrinol; 2018 Jul; 469():23-37. PubMed ID: 28552796
[TBL] [Abstract][Full Text] [Related]
11. Oncogenesis of Thyroid Cancer.
Younis E
Asian Pac J Cancer Prev; 2017 May; 18(5):1191-1199. PubMed ID: 28610401
[TBL] [Abstract][Full Text] [Related]
12. Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers.
Pozdeyev N; Gay LM; Sokol ES; Hartmaier R; Deaver KE; Davis S; French JD; Borre PV; LaBarbera DV; Tan AC; Schweppe RE; Fishbein L; Ross JS; Haugen BR; Bowles DW
Clin Cancer Res; 2018 Jul; 24(13):3059-3068. PubMed ID: 29615459
[No Abstract] [Full Text] [Related]
13. Clinical, pathological and genetic features of anaplastic and poorly differentiated thyroid cancer: A single institute experience.
Romei C; Tacito A; Molinaro E; Piaggi P; Cappagli V; Pieruzzi L; Matrone A; Viola D; Agate L; Torregrossa L; Ugolini C; Basolo F; De Napoli L; Curcio M; Ciampi R; Materazzi G; Vitti P; Elisei R
Oncol Lett; 2018 Jun; 15(6):9174-9182. PubMed ID: 29805648
[TBL] [Abstract][Full Text] [Related]
14. [Clinical characteristics and prognosis of anaplastic thyroid carcinoma].
Wang JF; Zhu XH; Tan Z; Ge MH
Zhonghua Zhong Liu Za Zhi; 2017 Jun; 39(6):434-438. PubMed ID: 28635233
[No Abstract] [Full Text] [Related]
15. Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies.
Molinaro E; Romei C; Biagini A; Sabini E; Agate L; Mazzeo S; Materazzi G; Sellari-Franceschini S; Ribechini A; Torregrossa L; Basolo F; Vitti P; Elisei R
Nat Rev Endocrinol; 2017 Nov; 13(11):644-660. PubMed ID: 28707679
[TBL] [Abstract][Full Text] [Related]
16. A Narrative Review of Genetic Alterations in Primary Thyroid Epithelial Cancer.
Romei C; Elisei R
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33572167
[TBL] [Abstract][Full Text] [Related]
17. Molecular Profile of Advanced Thyroid Carcinomas by Next-Generation Sequencing: Characterizing Tumors Beyond Diagnosis for Targeted Therapy.
Chen H; Luthra R; Routbort MJ; Patel KP; Cabanillas ME; Broaddus RR; Williams MD
Mol Cancer Ther; 2018 Jul; 17(7):1575-1584. PubMed ID: 29695638
[TBL] [Abstract][Full Text] [Related]
18. Clinical Utility of Circulating Cell-Free DNA Mutations in Anaplastic Thyroid Carcinoma.
Qin Y; Wang JR; Wang Y; Iyer P; Cote GJ; Busaidy NL; Dadu R; Zafereo M; Williams MD; Ferrarotto R; Gunn GB; Wei P; Patel K; Hofmann MC; Cabanillas ME
Thyroid; 2021 Aug; 31(8):1235-1243. PubMed ID: 33599171
[No Abstract] [Full Text] [Related]
19. Anaplastic Thyroid Carcinoma: Current Issues in Genomics and Therapeutics.
Abe I; Lam AK
Curr Oncol Rep; 2021 Feb; 23(3):31. PubMed ID: 33582932
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
